Previous Close | 21.89 |
Open | 21.58 |
Bid | 21.15 x 1300 |
Ask | 21.23 x 800 |
Day's Range | 21.07 - 21.89 |
52 Week Range | 10.89 - 29.25 |
Volume | |
Avg. Volume | 366,845 |
Market Cap | 1.105B |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for RNA
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avidity Biosciences, Inc. (RNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).